During the last session, Dynavax Technologies Corporation (NASDAQ:DVAX)’s traded shares were 1.69 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $11.50, reflecting an intraday gain of 4.26% or $0.47. The 52-week high for the DVAX share is $21.39, that puts it down -86.0 from that peak though still a striking 36.87% gain since the share price plummeted to a 52-week low of $7.26. The company’s market capitalization is $1.41B, and the average intraday trading volume over the past 10 days was 2.63 million shares, and the average trade volume was 2.86 million shares over the past three months.
Dynavax Technologies Corporation (DVAX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. DVAX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.22.
Dynavax Technologies Corporation (NASDAQ:DVAX) trade information
Dynavax Technologies Corporation (DVAX) registered a 4.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.26% in intraday trading to $11.50 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 9.84%, and it has moved by 6.48% in 30 days. Based on these gigs, the overall price performance for the year is 28.49%. The short interest in Dynavax Technologies Corporation (NASDAQ:DVAX) is 17.63 million shares and it means that shorts have 12.53 day(s) to cover.
The consensus price target of analysts on Wall Street is $25.75, which implies an increase of 55.34% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $30.00 respectively. As a result, DVAX is trading at a discount of -160.87% off the target high and -73.91% off the low.
Dynavax Technologies Corporation (DVAX) estimates and forecasts
Statistics show that Dynavax Technologies Corporation has outperformed its competitors in share price, compared to the industry in which it operates. Dynavax Technologies Corporation (DVAX) shares have gone down -18.67% during the last six months, with a year-to-date growth rate more than the industry average at 100.00% against 0.60. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 1,000.00% this quarter and then jump 225.00% in the quarter after that. In the rating firms’ projections, revenue will increase 46.30% compared to the previous financial year.
Revenue for the current quarter is expected to be $150.56 million as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $173.26 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $41.59 million and $108.27 million respectively. In this case, analysts expect current quarter sales to grow by 262.00% and then jump by 60.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 16.90%. While earnings are projected to return 172.60% in 2022.
Dynavax Technologies Corporation is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dynavax Technologies Corporation (NASDAQ:DVAX)’s Major holders
Dynavax Technologies Corporation insiders own 0.29% of total outstanding shares while institutional holders control 79.90%, with the float percentage being 80.13%. Federated Hermes, Inc. is the largest shareholder of the company, while 280 institutions own stock in it. As of Dec 30, 2021, the company held over 16.21 million shares (or 12.83% of all shares), a total value of $228.04 million in shares.
The next largest institutional holding, with 8.41 million shares, is of Bain Capital Life Sciences Investors, LLC’s that is approximately 6.66% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $118.4 million.
Also, the Mutual Funds coming in first place with the largest holdings of Dynavax Technologies Corporation (DVAX) shares are Federated Hermes Kaufmann Small Cap Fund and Federated Hermes Kaufmann Fund. Data provided on Jan 30, 2022 indicates that Federated Hermes Kaufmann Small Cap Fund owns about 8.0 million shares. This amounts to just over 6.33 percent of the company’s overall shares, with a $103.76 million market value. The same data shows that the other fund manager holds slightly less at 8.0 million, or about 6.33% of the stock, which is worth about $103.76 million.